trastuzumab
( trass-TOO-zoo-mab )
Other Name(s): Herceptin®, Ogivri™, Trazimera™, Herzuma®
Appearance: Clear, colourless solution
mixed into larger bags of fluids
Drug Monograph
Jan 2020
Eligibility Forms
Pertuzumab-Trastuzumab - Unresectable Locally Recurrent or Metastatic - Breast Cancer Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast CancerPatient Info Sheet
Jan 2020
What it is used for
- For treating certain types of cancers such as breast, stomach, or esophagus cancer.
- Trastuzumab is available as a biosimilar medication. See our biosimilar pamphlet for more information.